Following the modification and introduction of legislation governing the safety, development and use of regenerative and cell therapies in Japan in late 2014, companies in the space have been generally positive on the shape and impact of the supportive regulatory environment in the country – which has already led to the reimbursement and launch of several therapies.
Tokyo-based Healios K.K. is one such company. Formed in 2011 as Retina Institute Japan, a Fukuoka-based venture under Riken (Japan’s largest research organization for basic and applied science), the company listed on the Mothers high-tech market of the Tokyo Stock Exchange in 2015
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?